Clinical Trials: What to Expect in 2026 – A Preview of Trials Planned to Initiate and Estimated to Complete

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$695
Buy Report Download FREE Resources

Published: January 02, 2026 Report Code: GDHCHT657-ST

Select Item

Clinical Trials: What to Expect in 2026? Planned and completing trials by phase, geography, sponsor type, therapy area, and DCT adoption. Identify pipeline trends and benchmark competitors with GlobalData insights.

Gain Early Insight into the Global Clinical Trials Landscape for 2026

The clinical trials landscape is constantly evolving. Early visibility into planned and completing trials can provide a critical strategic advantage.

GlobalData’s Clinical Trials 2026 Analysis report offers a forward-looking view of trials expected to initiate and complete in 2026. You can explore how activity is distributed across phases, geographies, sponsor types, and therapy areas.

Moreover, the dataset is continuously updated as new trials are announced and existing studies evolve. As a result, you gain a dynamic and timely understanding of the global pipeline.

Report Value Proposition – Turn Trial Data into Strategic Advantage

This report goes beyond listing trials. It helps you interpret the direction of the global R&D pipeline.

With this report, you can:

  • Identify clinical trial pipeline trends for 2026 across key therapy areas
  • Analyze trial activity by phase, from early-stage to late-stage development
  • Understand industry vs non-industry sponsorship dynamics
  • Evaluate geographic distribution and emerging trial hubs
  • Track drug types and decentralized clinical trial (DCT) adoption
  • Benchmark your organization against top global sponsors

Built on GlobalData’s proprietary clinical trials database and trusted by Fortune 500 pharmaceutical companies and leading healthcare organizations, this report provides reliable insight to support high-stakes decisions.

Key Insights Across Clinical Trials in 2026

The report delivers detailed segmentation of planned and completing trials:

  • Trial phases: Understand where innovation is concentrated across Phase I–IV
  • Geography and country-level analysis: Identify key markets and emerging trial locations
  • Sponsor type: Compare activity between industry and non-industry players
  • Therapy areas and indications: Track where R&D investment is focused
  • Drug types: Evaluate modality trends across pipelines
  • Decentralized clinical trials (DCTs): Assess adoption across regions and therapy areas

In addition, the report highlights single-country vs multinational trials, helping you understand global vs localized development strategies.

Dynamic Data for a Changing Clinical Trials Environment

Clinical trials are fluid. Recruitment delays, protocol changes, and new study announcements can shift timelines. Therefore, this report provides a living dataset, updated throughout 2026.

It reflects real-world changes such as:

  • Trials moving through recruitment stages
  • Adjustments to completion timelines
  • Newly announced planned studies

This ensures your insights remain relevant and aligned with the latest developments.

Scope

What You Will Learn

The report provides a structured and comprehensive view of clinical trials:

  • Trials planned to initiate in 2026

  • Trials estimated to complete in 2026

  • Segmentation by phase, geography, sponsor type, therapy area, and indication

  • Analysis of drug types and DCT adoption trends

  • Insights into top sponsors and competitive landscape

In addition, detailed charts and figures support deeper analysis and benchmarking.

Target Buyers for This Report

This report is designed for professionals responsible for R&D, strategy, and investment decisions:

  • Clinical development and R&D leaders

  • Business development and licensing teams

  • Market intelligence and competitive strategy professionals

  • CRO and clinical operations teams

  • Healthcare investors and analysts

If you are making decisions about pipeline strategy, partnerships, or trial execution, this report can support your planning.

How Companies Use This Report

Organizations across the healthcare ecosystem use this report to drive decisions:

  • Pharmaceutical companies (e.g., Pfizer, Novartis, Roche): Monitor competitor pipelines and optimize clinical development strategies

  • Biotech firms: Identify partnership opportunities and prioritize high-growth therapy areas

  • CROs (Contract Research Organizations): Forecast demand for trial services across regions and phases

  • Investors and analysts: Evaluate pipeline strength and identify emerging areas of innovation

  • Healthcare strategy teams: Assess global trial activity and inform market entry or expansion plans

As a result, you can convert pipeline visibility into actionable strategy.

Reasons to Buy

Benchmark Against Leading Clinical Trial Sponsors

Understanding competitor activity is essential. Therefore, this report enables you to benchmark against:

  • Top pharmaceutical and biotech companies

  • Leading non-industry sponsors such as academic institutions and research organizations

  • By analyzing trial volumes, phases, and therapeutic focus, you can assess your competitive positioning and identify strategic gaps.

Built on Trusted Data and Global Expertise

This report is backed by GlobalData’s extensive clinical trials intelligence:

  • Trusted by Fortune 500 pharmaceutical companies and global healthcare leaders

  • Built on proprietary, continuously updated datasets

  • Developed by analysts with deep expertise in clinical research and drug development

Therefore, you can rely on the insights to guide critical decisions.

Act Now to Stay Ahead of Clinical Trial Trends

  • The ability to anticipate clinical trial activity can shape your competitive advantage. However, waiting for public results may leave you behind.

  • With early insight into planned and completing trials in 2026, you can proactively adjust your strategy, identify opportunities, and mitigate risks.

  • Access the report today to stay ahead of global clinical trial trends and strengthen your pipeline decisions.

Table of Contents

1. Tables and Figures

2. Executive Summary

3. Introduction

4. Clinical Trials Planned to Initiate 2026

5. Clinical Trials Estimated to Complete in 2026

6. Key Findings

7. Appendix

Figures

Figures 1 and 2: Planned clinical trials, by phase and sponsor type

Figure 3: Planned clinical trials, top industry sponsors, by phase

Figure 4: Planned clinical trials, top non-industry sponsors, by phase

Figure 5: Planned clinical trials, single-country or multinational, by sponsor type and phase

Figure 6: Planned clinical trials, regions, by phase

Figure 7: Planned clinical trials, regions, by phase and distribution

Figure 8: Planned clinical trials, country, by phase

Figure 9: Planned clinical trials, country, by phase and distribution

Figures 10 and 11: Planned clinical trials, drug type, by phase and distribution

Figure 12: Planned clinical trials, top therapy areas, by phase

Figure 13: Planned clinical trials, top therapy areas, by phase and distribution

Figure 14: Planned clinical trials, top indications, by phase

Figure 15: Planned clinical trials, top indications, by phase and distribution

Figures 16 and 17: Total planned DCTs, by therapeutic area

Figure 18: Clinical trials estimated to complete, by phase

Figures 19 and 20: Clinical trials estimated to complete, by status and phase distribution

Figure 21: Clinical trials estimated to complete, by sponsor type and phase

Figure 22: Clinical trials estimated to complete, by top industry sponsor and phase

Figure 23: Clinical trials estimated to complete, by top non-industry sponsor and phase

Figure 24: Single-country or multinational clinical trials estimated to complete, by region

Figure 25: Clinical trials estimated to complete, by country

Figure 26: Clinical trials estimated to complete, by therapy area and phase

Figures 27 and 28: Total DCTs estimated to complete, by region and single-country or multinational

Figure 29: DCTs estimated to complete, by therapy area and phase

Clinical Trials: What to Expect in 2026 – A Preview of Trials Planned to Initiate and Estimated to Complete standard reports
Currency USD
$695

Can be used by individual purchaser only

Most Popular
$1,042

Can be shared by unlimited users within one corporate location e.g. a regional office

$1,390

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Clinical Trials: What to Expect in 2026 – A Preview of Trials Planned to Initiate and Estimated to Complete was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clinical Trials: What to Expect in 2026 – A Preview of Trials Planned to Initiate and Estimated to Complete in real time.

  • Access a live Clinical Trials: What to Expect in 2026 – A Preview of Trials Planned to Initiate and Estimated to Complete dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more